The company plans to request a meeting with the FDA "to obtain further clarity on the approval path and timeline," Arena president and CEO Jack Lief said in a news release. Its maker, Arena Pharmaceuticals Inc, hasn’t given up yet.
Lorcaserin’s backers have argued that UPVC Butterfly Valve Company in China https://www.xiervalve.com/product/upvc-one-way-valve-butterfly-valve/upvc-butterfly-valve/ it offers a safer way to shed pounds than older medications linked to dangerous side effects.
Lorcaserin is part of a new wave of weight loss drugs seeking FDA approval.) December 12, 2011 - Hope for a new prescription weight-loss pill bit the dust over the weekend when the FDA rejected lorcaserin, calling any weight loss the drug produces in overweight people without diabetes "marginal. In 1997 Wyeth’s diet pill combination fen-phen was pulled from the market because of links to heart valve disease.
In July, an FDA advisory panel voted against approval for a drug called Qnexa after studies showed signs of heart palpitation and suicidal thoughts."
The FDA also cited concerns about tumors that developed in rats during early stage testing.
If lorcaserin had been approved, it would have been the first new prescription weight loss drug in more than a decade.
Lorcaserin’s backers have argued that UPVC Butterfly Valve Company in China https://www.xiervalve.com/product/upvc-one-way-valve-butterfly-valve/upvc-butterfly-valve/ it offers a safer way to shed pounds than older medications linked to dangerous side effects.
Lorcaserin is part of a new wave of weight loss drugs seeking FDA approval.) December 12, 2011 - Hope for a new prescription weight-loss pill bit the dust over the weekend when the FDA rejected lorcaserin, calling any weight loss the drug produces in overweight people without diabetes "marginal. In 1997 Wyeth’s diet pill combination fen-phen was pulled from the market because of links to heart valve disease.
In July, an FDA advisory panel voted against approval for a drug called Qnexa after studies showed signs of heart palpitation and suicidal thoughts."
The FDA also cited concerns about tumors that developed in rats during early stage testing.
If lorcaserin had been approved, it would have been the first new prescription weight loss drug in more than a decade.
コメント